La evidencia y el debate clínico del nuevo SLI-LNG 19,5 mg y su uso en la mujer nulípara a revisión

Abstract

The high rate of unwanted pregnancies results in a high social and economic impact worldwide. One of the most important strategies to reduce this problem is to increase the use of long-acting reversible contraceptive (LARC) methods, due to their efficacy, cost-effectiveness and the independence that these methods provide to their users. LARC methods have been shown to be safe for most women, regardless of age and parity. Kyleena® is the new LARC option. A new levonorgestrel intrauterine system (LNG-IUS) containing 19.5mg of levonorgestrel and provides a high contraceptive efficacy over 5years of use, with a cumulative 5-year Pearl Index of 0.29. Its small size allows a narrower insertion tube to be used and is more suitable for nulliparous women or those women with a narrower cervical canal. In addition to the contraceptive efficacy, Kyleena® may benefit users by providing a reduction in the duration and volume of menstrual bleeding. Many women and healthcare providers have shown certain resistance to intrauterine contraception due to the existence of misperceptions towards these methods. It is important to overcome these barriers, providing contrasted and truthful information about all existing methods, so that health professionals can provide complete contraceptive counselling for all women. This review approaches the clinically relevant aspects of the new LNG-IUS 19.5mg Kyleena® method and the benefits it can provide to women.